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Scientiﬁc Article

Intracranial Stereotactic Radiation Therapy With
a Jawless Ring Gantry Linear Accelerator
Equipped With New Dual Layer Multileaf
Collimator
Nels C. Knutson, PhD,* William R. Kennedy, MD,
Francisco J. Reynoso, PhD, Jiayuan Peng, MS, Lauren E. Henke, MD,
Eric Laugeman, MS, Michael Watts, MS, Jessica Hillard, MS,
Ana Heermann, AS, Geoffrey D. Hugo, PhD, Sasa Mutic, PhD and
Bin Cai, PhD*
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
Received 9 August 2019; revised 27 December 2019; accepted 22 January 2020

Abstract
Purpose: To test the feasibility of a simpliﬁed, robust, workﬂow for intracranial stereotactic radiation therapy (SRT) using a ring gantry
linear accelerator (RGLA) equipped with a dual-layer stacked, staggered, and interdigitating multileaf collimator.
Materials and Methods: Twenty recent clinical SRT cases treated using a radiosurgery c-arm linear accelerator were anonymized. From
these data sets, a new planning workﬂow was developed and used to replan these cases, which then were compared to their clinical
counterparts. Population-based dose-volume histograms were analyzed for target coverage and sparing of healthy brain. All plans
underwent plan review and quality assurance and were delivered on an end-to-end veriﬁcation phantom using image guidance to
simulate treatment.
Results: The RGLA plans were able to meet departmental standards for target coverage and organ-at-risk sparing and showed plan
quality similar to the clinical plans. RGLA plans showed increases in the 50% isodose in the axial plane but decreases in the sagittal and
coronal planes. There were no statistically signiﬁcant differences in the homogeneity index or number of monitor units between the 2
systems. There were statistically signiﬁcant increases in conformity and gradient indices, with median values of 1.09 versus 1.11 and
2.82 versus 3.13, respectively, for the c-arm versus RGLA plans. These differences were not believed to be clinically signiﬁcant because
they met clinical goals. The population-based dose-volume histograms showed target coverage and organ-at-risk sparing similar to that
of the clinical plans. All plans were able to meet the departmental quality assurance requirements and were delivered under image
guidance on an end-to-end phantom with measurements agreeing within 3% of the expected value. RGLA plans showed a median
reduction in delivery time of z50%.
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Conclusions: This work describes a simpliﬁed and efﬁcient workﬂow that could reduce treatment times and expand access to SRT to
centers using an RGLA.
Ó 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Stereotactic radiosurgery (SRS) is an established modality in the management of brain metastases, providing
local control and survival comparable to whole brain
radiation therapy with decreased potential for neurocognitive decline in both the deﬁnitive and postoperative
settings.1-3 As the incidence of brain metastases steadily
increases due to increased utilization of magnetic resonance imaging and improvements in systemic therapy,
both the need for and utilization of SRS have increased
accordingly.4-6
Historically, SRS has been delivered in a single fraction, with dosing typically as per The Radiation Therapy
Oncology Group 90-11 study.7 Brain radiation necrosis
(RN) is an important late complication of SRS that may
lead to irreversible neurologic symptoms in some patients.
Tumor size, prescription dose, and the volume of normal
brain exposed to 12 Gy (V12) >10 cm3 are all factors
implicated in the development of RN.8,9 Therefore, the
use of single-fraction SRS for treating large or irregular
intracranial volumes is limited by concerns of RN.
Furthermore, SRS requires high accuracy of the setup,
treatment planning, and delivery process. This comes at
the cost of requiring increased complexity and precision
of the immobilization devices, imaging guidance modalities, and mechanical accuracy of the linear accelerator
(linac). This is often accomplished by the use of rigid
immobilization stereotactic frames or, in frameless SRS
cases, 6 degrees of freedom couches with surface monitoring or intrafractional imaging systems.
Multifraction SRS or stereotactic radiation therapy
(SRT), typically given in 3 to 5 fractions to doses of 24 to
35 Gy, is an emerging alternative to single-fraction SRS,
particularly for metastases greater than 2 cm in size or for
large, irregular postoperative cavities that would otherwise prove challenging to treat with single-fraction SRS.
The goal of this approach is to minimize the risk of RN
while maintaining high local control rates. Early retrospective comparisons of multiple versus single-fraction
regimens have had promising results, with at least
equivalent local control rates and lower neurologic
adverse events in both the upfront and postoperative
settings.10,11 However, no randomized comparisons have
been published to date, and the optimal dose and fractionation scheme has yet to be established.
To address the global need for image guided radiation
therapy, a new-generation ring gantry linac, the Halcyon
(Varian Medical System, Palo Alto, CA), recently was

released. Halcyon is capable of providing a 6 MV ﬂattening ﬁlter free beam with rapid gantry rotation up to 4
rotations per minute. It has a compact jawless treatment
head equipped with double stack multileaf collimator
(MLC). Previous studies have shown promising results in
terms of superior imaging quality, improved treatment
efﬁciency, simpliﬁed operations, and acceptable plan
quality.12-15 However, to our knowledge, there is no study
focusing on the evaluation and implementation of fractioned brain SRS study using this new device.
In this study, we test the feasibility of treatment
planning and delivery for intracranial stereotactic radiation therapy on this novel ring gantry linear accelerator.
We evaluate (1) the dosimetric performance of the
coplanar beam Halcyon plans compared with traditional
plans using noncoplanar beams, (2) the feasibility of
standardizing planning procedures to reduce planning
variations and improve efﬁciency, and (3) the simulated
treatment delivery performance (end-to-end testing) on an
anthropomorphic phantom to test plan deliverability, accuracy under image guidance, and operational efﬁciency
gain.

Methods and Materials
After review from the Human Research Protection
Ofﬁce at our institution, our retrospective institutional
review boardeexempt review of patients was approved
(HRPO #201901143).
Twenty patients who had undergone stereotactic radiation therapy who were clinically treated on a c-arm linac
(Edge, Varian Medical Systems) equipped with a 6 degrees of freedom couch and high-deﬁnition MLC were
selected for inclusion. Eclipse V13.7 (Varian Medical
Systems) was used for the clinically delivered plans in all
cases. Each case used volumetric modulated arc therapy
(VMAT)16 with 1 to 2 axial half arcs and 2 to 4 noncoplanar half arcs using 6 ﬂattening ﬁlter free beam with a
dose rate of 1400 monitor units per minute. All cases were
prescribed 30 Gy in 5 fractions to the planning target
volume (PTV). In each case the gross tumor volume
(GTV) was deﬁned on the T1 weighted magnetic resonance imaging post contrast by the MD. A 2 mm PTV
expansion was used in each case. The median GTV was
14.4 mL (range, 5.7-43.7 mL), and the median PTV was
23.5 mL (range, 11.1-55.2 mL).
For each case, the clinical data sets were anonymized
by a third-party honest broker and imported into a
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Volumetric modulated arc therapy optimization objectives

Optimization object

Optimization speciﬁcation

Typical relative weight

OAR
NTO

Upper: Whatever is required to meet constraints
Start distance Z 0 mm, start dose Z 101%,
end dose Z 20%, fall off Z 0.25
Lower: V32 Gy Z 100%; upper: V42.5 Gy Z 0%
Lower: V30.5 Gy Z 100%
Upper: V36 Gy Z 0%
Upper: V30 Gy Z 0%
Upper: V15 Gy Z 0%
Max MU <1800

Whatever is required
150

GTV
PTV
PTV-GTV
Ring touching PTV
Ring 5 mm from PTV
MUR

120 and 100, respectively
110
100
80
80
80

Abbreviations: GTV Z gross tumor volume; NTO Z normal tissue objective; OAR Z organ at risk; PTV Z planning target volume; MUR Z
monitor unit ratio.

nonclinical treatment planning station. The original clinical plan data was then conﬁrmed and recorded. A new
treatment plan was then created using the Halcyon. Each
plan was calculated using the analytical anisotropic algorithm17-19 beam model with a 1 mm dose grid, as used
in the original clinical plans. A single isocenter and 4 full
arc beam geometry was set up, using the arc geometry
tool allowing the treatment planning system to select the
optimal collimator angles and ﬁne tune the isocenter
location. The 4 arcs with unique collimator angles were
chosen to match our clinical experience and follows
similar experiences from the literature.14,20 VMAT was
used with the photon optimizer (PO v15.6) using
convergence mode, which enforces stricter criteria for
convergence between multiresolution levels in the

Table 2

Plan quality metrics and organ at risk constraints

Quantity Deﬁnition

Clinical goal
(acceptable variation)

CI
GI
R50
HI
GM

1-1.2 (1-1.5)
<3 (<4)
<4 (<4.5)
1.1-1.55
<0.8 cm (<1.2 cm)

MUR

V30Gy/VPTV
V15Gy/V30Gy
V15Gy/VPTV
Max dose/30 Gy
Distance between 30 Gy
and 15 Gy equivalent
spheres
No. of monitor units/3000
cGy

<4 (<5)

Organ at risk

Volume (mL)

Dose constraint (Gy)

Brain stem

0.5
0.03
1.2
0.35
0.03
0.2
0.03
0.03

23
31
14.5
23
30
23
25
25

Spinal cord and
medulla
Optics
Cochlea

Abbreviations: CI Z conformity index; GI Z gradient index; GM Z
gradient measure; HI Z homogeneity index; MUR Z monitor unit
ratio; R50 Z relative ratio of the 50 isodose volume hetero.

optimization process. All optimizations were restarted
after intermediate dose calculation at the third multiresolution level. This version of the Halcyon allows for
full interdigitating and independent travel of stacked and
staggered MLCs. In each case, a ring structure touching
the PTV, a ring structure 5 mm from the PTV, and a
contour covering the patients face were used for optimization. The normal tissue objective and maximum
monitor unit objectives were also used in each case. In all
cases, organ-at-risk (OAR) tolerances from American
Association of Physicists in Medicine Task Group 10121
were respected and included in the optimization in
needed. A minimum PTV coverage of the prescription
isodose >98% of the PTV was used. In each case the plan
was normalized to match the clinical plan while
respecting OAR doses. A maximum dose to the ring
touching the PTV of 3050 cGy, a max dose to the ring 5
mm from the PTV of 1500 cGy, and a maximum dose of
200 cGy to the patient’s face were used for VMAT
optimization. In all cases, we optimized on the GTV to
force the hotspot to be within the GTV and not on the
edges of the PTV. The optimization parameters used can
be seen in Table 1.
In each case, plans were evaluated qualitatively by
reviewing isodose lines and dose-volume histograms
(DVHs)22 and quantitatively by collecting plan quality
metrics and DVH data. For all cases the conformity index
(CI Z V30 Gy/volume of PTV), gradient index (GI Z V15
Gy/V30 Gy), gradient measure (GM Z distance between
equivalent spheres of the 30 Gy isodose to the 15 Gy
isodose), homogeneity index (HI Z max dose/30 Gy), R50
Z V15 Gy/volume of PTV, and monitor unit ratio (MUR
Z total MU/3000 cGy) were collected. A summary of these
metrics and our departmental standards is given in Table 2.
Box and swarm plots of each parameter for both the original
clinical plans and the ring gantry plans were created. Wilcoxon signed-rank testing was used to compare the 2 paired
data sets. In all cases, DVH data was exported for comparison using in-house developed software to compare
groups of patients by calculating the median and inner
fences of the DVH distributions across groups of plans. This
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Visual comparison of stereotactic radiation therapy plans with c-arm and ring gantry linear accelerators.

was completed for all clinical plans and ring gantry plans for
the PTV and brain structures to compare the 2 sets of plans.
Each case followed our clinical workﬂow and was
reviewed by a physicist and radiation oncologist. Each
plan was reviewed for plan quality and deliverability issues by a physicist in a formal precheck. Any issues seen
at this step were resolved before radiation oncologist review. Once each precheck was approved, each plan was
reviewed by a radiation oncologist and approved. Once
approved, each case underwent quality assurance (QA)
measurements using portal dosimetry for a 2-dimensional
ﬂuence map QA and ion chamber measurements for 1dimensional absolute dose measurement. A 2-dimensional
gamma analysis23,24 with a 2%/2 mm criterion was used
for the portal dosimetry data. A 3% dose difference criterion was used for the ionization chamber measurements.
Upon completion of the clinical workﬂow steps, for each
case, a stereotactic end-to-end testing phantom was set up,
imaged using kilovoltage cone beam computed tomography, and then treated. The total treatment time from
beam on to beam off and dose reading from an ionization
chamber inside the phantom were recorded in each case.

Results
All plans were deemed to meet departmental clinical
standards by a physicist and radiation oncologist for target
coverage and OAR sparing. Sample visual comparison of

a clinical c-arm linac plan and the corresponding ring
gantry linac plan are shown in Figure 1. Overall, we
observed an increase in the distance between PTV and the
isodose lines below 1500 cGy in the axial plane for the
ring gantry plans. However, in the superoinferior plane,
there was a reduction in the distance from the PTV to
isodose lines at and below 1500 cGy for the ring gantry
plans compared with the clinical c-arm plans. Isodose
lines above 1500 cGy line were similar between the 2
plans types.
Box plots and swarm plots for plan quality metrics
between the clinical plans and the ring gantry plans across
all patients are shown in Figure 2. There was no statistically signiﬁcant difference in the number of monitor units
used or the homogeneity index. There were slight but
statistically signiﬁcant increases in CI, GI, R50, and GM.
The median values of CI, GI, R50, and GM were 1.09
versus 1.11, 2.82 versus 3.13, 3.13 versus 3.53, and 0.72
versus 0.80 cm, respectively, for the c-arm versus ring
gantry plans. Although these differences were statistically
signiﬁcant, they were not believed to be clinically signiﬁcant in this patient cohort, given that all plan parameters for all plans fell within the clinically acceptable
range.
Population-based DVHs results for the brain and PTVs
for the c-arm and ring gantry linacs are shown in Figure 3.
The median of the populations is shown by bold lines and
the corresponding inner fences (ﬁrst quartile minus 1.5
times the interquartile range and the third quartile plus 1.5
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Figure 2
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Box and swarm plots of plan quality parameters for Halcyon stereotactic radiation therapy plans and the clinical plans.

times interquartile range) are shown by dashed lines for
the ring gantry (black) and the c-arm (red) plans. All plans
have clinically acceptable dose to the normal brain, as
shown in Figure 3a. The median brain volume for ring
gantry plans was slightly reduced compared with c-arm
for doses under 150 cGy and slightly increased for doses
above 150 cGy to 1500 cGy. Volumes receiving doses
above 1500 cGy are nearly identical because these are
dictated by the target coverage. Figure 3B shows very
similar target coverage achieved between the 2 systems,
with the ring gantry having slightly more coverage from
3000 to 3700 cGy and slightly less from 3800 cGy to
4100 cGy. Note that the sharp changes in the median
(Fig 3b) are caused from the variation in homogeneity
index of the individual plans. When an individual PTV
coverage metric goes to zero, it is no longer included in
the population calculation; however, right before reaching
zero it is included, thus causing rapid changes in the
median. All plans had clinically acceptable coverage.

All plans met current clinical QA standards for treatment: being within 3% of expected for an ionization
chamber measurement and having a minimum of 90% of
points, yielding a gamma value of 1 with a 2%/2 mm
criterion. The median ion chamberemeasured percent
difference from expected was 1.6% (range, e2.7% to
2.9%) for the ring gantry system versus 0.01% (range,
e2.5% to þ2.9%) for the clinical c-arm system. Similarly, the portal dosimetry results yielded a median pass
rate of 100% (range, 98.8%-100%) with a 2%/2 mm
gamma criterion per ﬁeld. By comparison, the clinical
c-arm plans yielded 99.4% (range, 95.4%-100%).
Ion chamber measurements completed under kilovoltage cone beam computed tomography image guidance
in the end-to-end phantom agreed within 3% of the
expected dose. The median percent difference of the
expected to measured dose was þ0.7% (range, e2% to
þ3%). Treatment times for all cases were reduced by
almost 50% using the ring gantry delivery. The median
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Figure 3 Planning target volume (PTV) and brain dose-volume histogram data for Halcyon stereotactic radiation therapy plans and
the clinical plans.

time for the treatment delivery using the ring gantry was 2
minutes and 46 seconds (range, 2 minutes 36 seconds to 3
minutes 14 seconds), whereas clinical plans had a median
delivery time of 4 minutes 43 seconds (range, 3 minutes
13 seconds to 6 minutes 21 seconds). Figure 4 summarizes of the QA results.

Discussion
In this study, we evaluated the feasibility of fractionated intracranial stereotactic radiation therapy planning

and delivery using a novel ring-gantry system. We found
that plans made on the Halcyon system had similar
dosimetric plan quality to standard clinically deliver
plans. The Halcyon system also enabled a simpliﬁed,
robust, and accurate workﬂow with reduced treatment
delivery times.
The Halcyon is one of the latest ring gantry systems;
however, previous ring gantry systems such as TomoTherapy (Accuray, Sunnyvale CA), the Vero (BrainLab,
Munich DE), and the MRidian (ViewRay, Oakwood
Village, OH) have all been proposed for use in intercranial SRT or SRS. This work showed plan quality
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Figure 4 Summary of quality assurance (QA) results for stereotactic radiation therapy plans with the ion chamber results shown on
top and portal dosimetry pass rates per ﬁeld shown on bottom.

metrics similar to or better than reported in the literature
for these other ring gantry delivery systems.25-29
In addition to being faster in delivery, the Halcyon also
has several beneﬁts with the ring-gantry design. There are
no risks of the rotating gantry colliding with the patient
with the ring gantry geometry, potentially improving patient safety. Any potential collisions with ring and the
patient or couch are modeled directly in the treatment
planning system. Given the 1-m bore, lack of couch
rotation, and relatively small size of the head relative to
the bore size, the likelihood of a collision issue is very
low and did not occur in any of the cases in this study.
Given the lack of couch rotations, there is also no couch
walkout (ie, a shift in the couch isocenter with rotation
with respect to the radiation isocenter due to couch rotation), which simpliﬁes the QA needed before the SRT
procedures. This increase in standardization in the treatment planning of these SRT cases could reduce potential
errors that can occur in the planning process.
The lack of 6 degrees of freedom corrections is a
limitation of the current generation of Halcyon. Treating
with the isocenter at the center of rotation of the target
will minimize the effects of setup rotation on the plan.30,31
Fractionation used in SRT also allows for this uncertainty
to be spread over a few fractions and blur the dose instead
of making a single systematic shift in the dose, as seen in
SRS. Thus, SRT is the more appealing option for the
Halcyon in its current form.
This study is a proof of principle study and was
completed in a limited patient population set with
limited statistical analysis due to the relatively small
sample size. Given these limitations it is difﬁcult to
draw strong statistical conclusions of equivalency to an

SRS c-arm linac. However, we have shown in our
patient population with our clinical guidelines that the
Halcyon was able to meet our goals, often with reduced
variability of our current clinical practice. The Halcyon
could be promising and viable option if access to an
SRS linac is limited. Additional work would need to be
completed to ensure this methodology could be applied
to a different patient population with different clinical
goals, although these results are promising for future
clinical use.
The Halcyon offers reduced cost of purchase and
maintenance and comes preconﬁgured, reducing the time
and cost for commissioning. Even if one concedes that
the Halcyon only provides noninferior clinical plan
quality, this would still represent a potential value increase. In particular as described by Porter et al, value to
the patient should be measured as clinical outcome per
cost to the achieve them.32 Assuming the clinical outcomes could be noninferior, and given the reduced cost of
the Halcyon, this would represent a higher value to the
patient. Future work will show if this is in fact true;
however, this work seems to indicate it is at least feasible.
Even if one concedes the Halcyon could be slightly
inferior to traditional c-arm linear accelerators in some
aspects, the fact that there could still be increased value to
patients and given that the Halcyon could lead to more
access to SRT in resource-limited areas of the market
could indicate a potential disruptive innovation occurring,
as described by Christensen et al and Hwang et al.33,34
Again, time will tell the full impact of the Halcyon on
the radiation therapy market, but increasing access to
SRT at reduced costs could potentially be a large innovation to the ﬁeld.
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Conclusions
This work has demonstrated the feasibility and accuracy of a simpliﬁed, robust workﬂow for intracranial
stereotactic radiation therapy using a ring gantry linac.
This could increase access to a standardized and robust
approach to SRT for a larger patient population.
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